domest diabet drug player ramp
figur major driver increas diabet market china
driver volum growth
driver asp growth
china largest potenti diabet market world-wide china
diabet market quit under-penetrated china account
global diabet popul diabet drug market
account global diabet drug market see china
diabet market doubl next five year reach bn driven
volum asp chines patient start pay attent
chronic diseas diabet lead complic health
risk higher treatment rate expand insur coverag emerg
treatment method major driver
domest player gain market share mnc mnc domin
china diabet drug market drug class market
share insulin tradit oral drug class
new drug class see strong trend domest compani gain
market share due approv domest product mnc focu
penetr new product price advantag polici support
domest player estim domest compani
market share tradit drug class share insulin market
five new-drug-class drug approv next three year
diabet sector defens sector headwind see diabet
sector defens recent polici includ price cut challeng
mnc major diabet product alreadi includ medic
insur thu compani littl pressur cut price includ
insur diabet product domest compani alreadi
price larg discount product averag besid
technic barrier diabet drug especi insulin quit high
lead oligopoli market limit competit
initi tonghua dongbao unit lab outperform
initi coverag tonghua dongbao outperform tp
upsid unit lab outperform tp
upsid like two oligopoli china diabet market
expect new blockbust product near futur
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
charl martineau univers toronto focu chart tabl
figur china world diabet
patient
figur china diabet drug market doubl
figur major driver china diabet drug
figur mnc domin insulin market
market share
driver volum growth
driver asp growth
figur product domest compani price
figur domest compani gain market
share overal diabet market
charl martineau univers toronto china account
global
driver asp
volum
domest player
market share
insulin
us
market gap
initi tonghua
dongbao unit
lab
domest diabet drug player ramp
initi china diabet drug sector believ prime growth
opportun china account global diabet popul
expect chines diabet drug market grow compound-annual-growth-rate term sale
almost reach bn doubl market size within next
five year growth primarili exist larg diabet popul base
increas pool diabet patient receiv treatment well higher asp
upgrad diabet drug product mix
china diabet drug market doubl
drive forc major contributor doubl china diabet drug
market within five year roughli carv driver volum
asp growth volum growth come increas diabet patient higher
diabet diagnos rate rais public awar chronic diseas
increas rate treatment better afford asp growth driven latest
revis made china nation drug reimburs list ndrl increas
insur coverag diabet drug dollar amount number therapi
well emerg therapi forecast gain market share alter diabet
drug portfolio mix china caus increas overal willing pay patient
mnc domin china diabet drug market drug class
market share insulin tradit oral drug class new
drug class forese strong trend domest compani gain market share due
approv domest product mnc focu penetr new product
price advantag polici support domest player estim domest
compani market share tradit drug class share
insulin market five new drug class approv next three year
larg upsid compar studi us
china
lastli look potenti growth china diabet drug market compar
china us market largest diabet drug market current compar
treatment rate current prescript best-sel drug china versu
us draw pictur matur diabet drug market studi us market
find gap two though china diabet market match uss
cost per capita drug price cheaper china see larg upsid potenti
increas treatment rate upgrad therapi
initi coverag tonghua dongbao outperform tp
upsid unit lab outperform tp upsid like two
compani lead posit china diabet market expect new
blockbust product near futur tonghua dongbao pure diabet player
diabet busi contribut revenu estim
compani deliv revenu compound-annual-growth-rate net profit compound-annual-growth-rate next three year
lead posit diabet strong growth believ deserv premium
larg pharma name current under-valued unit lab current
trade one-year forward price-to-earnings much lower industri averag believ
under-valued valuat upsid support stabl price
ramp insulin glargin sale
note price octob stock rate cover
compani data thomson reuter datastream estim cover compani credit suiss estim cover compani
charl martineau univers toronto tabl content
focu chart tabl
domest diabet drug player ramp
china diabet drug market doubl
larg upsid compar studi us
china diabet drug market doubl
china diabet drug market doubl next five
insulin market domin growth
defens recent polici
larg upsid compar studi us china
leader grassroot insulin market
china insulin market tripl
leader grassroot insulin market
initi outperform tp
china insulin market tripl
human insulin market share china remain
leader grassroot insulin market
initi outperform tp
holt view tonghua
lead new player china insulin market
rich pipelin diabet drug
benefit grow intermedi
initi outperform tp
lead new player china insulin market
solid growth human insulin
ramp insulin glargin sale
rich pipelin diabet drug
insulin aspart approv near
benefit grow intermedi price
initi outperform tp
holt view unit
charl martineau univers toronto diabet sector
defens recent
china diabet drug market doubl
china world diabet patient second largest diabet drug
market follow us howev spend per capita china
spend per capita diabet drug us china diabet market sale
bn per data forecast china diabet drug market
grow compound-annual-growth-rate outpac global growth rate market growth
driven larger diabet patient base higher diagnos rate upgrad
prescript view longer term china continu shorten gap
us term therapi cost per capita
diabet sector defens polici headwind china healthcar sector
correct lot recent due polici headwind includ oncolog drug price cut
gpo group purchas organis gener see diabet sector
quit defens headwind major diabet product alreadi
includ medic insur thu compani seldom pressur cut price
includ insur list diabet product domest compani alreadi
price larg discount product mnc averag besid
technic barrier diabet drug especi insulin quit high led
oligopoli market less intens competit
diabet chronic condit associ abnorm high level sugar glucos
bloodstream prolong period mn patient global
estim mn death caus directli diabet accord
world organ china world diabet patient due
obes carbohydrate-ori diet
figur type diabet domin market
around diabet patient
caus defici insulin product
account peopl diabet
diagnosi hemoglobin level higher major criteria random plasma glucos mg/dl
higher fast plasma glucos dl higher
caus bodi ineffect use insulin
treatment start lifestyl modif includ diet physic activ medic sulfonylurea meglitinibd
thiazolidinedion inhibitor receptor agonist inhibitor insulin therapi combo
occur pregnanc
treatment diet physic activ add insulin control
base frost sullivan data mn diabet world-wide
approxim type diabet number type diabet
expect grow mn per per idf
diabet feder accord global total healthcar expenditur
diabet reach bn bn develop market
charl martineau univers toronto figur global diabet popul grow
compound-annual-growth-rate
figur global diabet drug market
maintain solid pace growth
estim global diabet drug market maintain solid growth next ten year
around compound-annual-growth-rate reach bn growth driven age
popul base global higher diagnosi ratio emerg market well
applic emerg drug therapi method
current diabet therapi start diet control sport activ case
glucos level control follow line therapi tradit oral
drug class insulin frequent insulin inject
figur line therapi diabet treatment
offici chines guidelin treatment type diabet
china diabet drug market doubl next
current china second-largest diabet drug market follow us howev
spend per capita china diabet drug us china diabet
market sale around bn per data forecast china
diabet drug market grow compound-annual-growth-rate outpac global growth
rate market growth driven larger diabet patient base higher diagnos rate
upgrad prescript view longer term china continu
shorten gap us term therapi cost per capita
figur forecast market compound-annual-growth-rate china diabet drug
believ five key driver growth contribut volum growth
averag sell price asp increas enabl diabet drug manufactur china
well overal china diabet drug market experi strong upsid growth
potenti within next five-to-ten year
figur driver growth china diabet market due increas diabet patient volum
driver volum growth
driver asp growth
base data china account global diabet popul
versu us howev china diabet drug market current compris
less global market china diabet market account
us market diabet drug spend per patient account us
look us market size benchmark see signific room
potenti growth china
figur china world diabet
patient
figur world diabet drug market
major driver volum growth
increas diabet patient due higher obes rate age popul
china diabet patient increas past ten year due higher obes
rate age popul number reach mn mean around
china popul diabet per data besid accord jama
journal american medic associ prediabet nearli china
prediabet defin stage glucos level higher normal
reach stage diabet prediabet popul expos
higher risk diabet
figur see diabet patient grow mn
caus diabet still unknown factor rais risk diabet
known factor includ overweight obes greater china
obes rate increas anoth import factor
diabet incidencequit studi shown incid diabet
higher popul older
figur china obes rate
age
increas diagnos rate driven better medic consult avail
also see diagnos rate increas rais public health awar
commun health centr chc community-bas system lower incom
household rural region
part five-year china central govern push
seri healthcar reform benefit low incom household rural region
use chc one major diseas identifi within plan diagnos
rate diabet increas expect continu increas due
higher penetr rate public health access urban rural resid
forecast china diagnos rate surpass global diagnos rate
figur forecast high growth rate china
diagnosi diabet
figur allow china surpass global
averag diagnos rate
increas treatment rate better afford
anoth drive forc contribut overal increas china diabet drug
market increas patient current diabet seek treatment
option current china diabet patient blood sugar ratio
well control around diagnos patient treat better
insur coverag diabet drug better realis chronic diseas
manag see treatment rate increas
figur china diabet popul
undergo treatment
figur forecast treatment rate
increas
treatment case diagnos case
major driver asp growth
ndrl inclus new therapi
china central govern revis ndrl contain list
medicin cover nation medic insur last list publish
revis list grown includ western
tradit chines medicin diabet drug seen beneficiari latest
revis ndrl current form ndrl individu therapi
use diabet includ oral agent tradit chines medicin tcm
diabet drug insulin product
figur revis ndrl relat diabet drug
revis made broader coverag
product upgrad categori categori
revis made broader coverag
new addit made list categori drug categori drug
ndrl reimburs two revis made list see two
drug upgrad categori categori categori drug ndrl
reimburs chang made increas overal diabet product mix ndrl
well increas overal reimburs quota diabet drug believ
two factor contribut increas compound-annual-growth-rate asp
diabet drug china
figur compound-annual-growth-rate growth asp
partli due revis made ndrl
figur diabet therapi excl tcm cover
public insur china revis ndrl
china diabet drug market still domin tradit oral class
tradit oral drug still account diabet drug market china versu
us mainli due fact drug well cover ndrl
list reimburs rate doctor prescript habit tradit oral agent
includ drug biguanid -glucosidas inhibitor sulfonylurea tzd
glinid newer drug class market includ inhibitor
analog
charl martineau univers toronto figur tradit oral drug market
share china
figur tradit oral drug
market share us
us diabet drug market domin insulin insulin analog account
around market per evalu pharma insulin insulin analog
alway continu market leader diabet drug offer
entrant new drug class inhibitor analog
gain market share tradit oral agent major player oper
global market diabet drug includ novo nordisk eli lilli sanofi merck co
boehringer-ingelheim astrazeneca johnson johnson amongst other
figur chang us diabet drug market surg
popular drug use diabet therapi china outsid insulin
still oral agent within tradit drug class believ follow global
trend newer drug class begin pick speed china market chang
top diabet drug sale list near futur trend crucial follow
charl martineau univers toronto chang product mix landscap influenc asp dramat
contribut greatli growth rate china diabet drug market
figur best-sel drug china
averag price sampl product within categori newer drug
class significantli higher price within tradit drug class given five
inhibitor one therapi includ ndrl revis
overal trend develop countri usag newer drug class diabet
treatment expect asp increas accordingli contribut forecast
compound-annual-growth-rate asp
figur upgrad new drug class increas asp
insulin analog
upgrad prescript new drug includ medic insur
see diabet market grow higher patient asp new ndrl
product product includ
base analysi done look driver volum asp growth
complet bottom forecast diabet drug market china allow us
forecast near doubl market within next five year use diagnos
ratio treatment ratio asp major driver base case grey sky blue
sky scenario compound-annual-growth-rate base assumpt steadi increas
diagnos ratio higher treatment rate due greater access medic centr
like rise asp due increas insur coverag emerg therapi
base case scenario base case scenario base keep growth rate
diagnos ratio treatment ratio past five year also assum asp
grow around per year match histor trend factor upgrad therapi
grey sky scenario cut diagnos ratio treatment ratio growth pp
year assum asp growth everi year
sky scenario add pp diagnos ratio treatment ratio growth
year assum asp growth everi year
insulin market domin growth
china insulin market grown rapidli volum compound-annual-growth-rate sale
compound-annual-growth-rate per im data higher sale compound-annual-growth-rate come prescript
upgrad chang human insulin insulin analog higher asp
averag spend per patient market reach around bn term
sale estim market tripl bn believ
insulin player china market largest winner next five year
insulin contribut diabet drug growth tonghua dongbao unit
lab major list player
charl martineau univers toronto figur china insulin market tripl bn vs
note market size calcul ex-factori price compani data credit suiss estim
insulin account around china anti-diabet drug sale versu
global market leav insulin larg potenti grow term market
share anti-diabet market besid penetr rate insulin among diabet
patient around
growth gener larger diabet patient popul increas diagnos
rate higher penetr insulin treatment better patient complianc larger volum
insulin use per patient treatment upgrad within insulin treatment human insulin
insulin analog
figur catalyst drive insulin market growth china
rate insulin
upgrad
human insulin
defens recent polici headwind
see diabet sector defens recent polici includ price cut challeng
mnc major diabet product alreadi includ medic insur thu
compani littl pressur cut price includ insur domest compani
diabet product alreadi price larg discount mnc product averag
besid manufactur technic barrier produc diabet drug especi insulin
quit high led less competit oligopoli market
tradit diabet drug insulin china alreadi sell larg discount
price oversea market human insulin price stabl past
five year increas slightli lantu insulin glargin sanofi sell
around per month china around cost us
figur monthli cost us lantu china versu us
lantu china
lantu us
china diabet market still domin mnc major drug class
mnc account insulin market tradit oral drug
class new drug class besid two
best-sel diabet drug manufactur domest compani even
tradit oral drug whose patent expir three year ago market
still domin mnc acarbos patent expir china howev bayer still
command market share
even though market still domin mnc see trend domest
player take market share mnc tradit diabet drug market
past three year exampl zhongmei huadong acarbos market share increas
see domest compani win market share
mnc given drug price advantag especi drug pass
bioequival test prove efficaci mnc drug
believ domest compani market share increas driven pressur
insur cost control pass test approv domest compani
figur mnc domin major drug class china
new drug class diabet drug market mnc
licens byetta bydureon az
tradit drug class diabet drug mnc
diabet drug market mnc
price advantag major driver domest compani gain market share refer
two drug categoriesth tradit oral drug class insulin analogsand find
domest compani gener biosimilar sell around discount
compar mnc product chines govern announc sever polici
past half yearsuch gpo group purchas organis gener
motiv prescript gener order lower insur payment
figur price acarbos tablet
figur price insulin glargin
one import factor price advantag lower expens exampl tonghua
dongbao spent around total sale much lower spent
big pharma name china global peer mainli result
domest player focus pipelin fact current approv diabet
drug except tradit china medicin gener biosimilar cost
develop gener biosimilar much lower innov drug besid
diabet drug compani tonghua dongbao ganle focu
develop diabet drug note focus pipelin help improv effici
exampl novo nordisk whose sale contribut focus treatment
area lower expens per sale compar larg pharma mnc
 expens percentag total sale may increas compani diabet
product enter late stage clinic trial stage long run believ
 expens diabet compani lower big pharma compani
given focus pipelin well mnc mainli due lower payment
scientist china vs regul market
figur cost diabet player versu compani
note use expens per finish product unit lab
anoth factor support domest compani price advantag larg capac per
singl ferment tonghua dongbao three ferment largest singl
dive major drug class see domest compani gain market
share mnc
tradit oral agent domest player benefit low price
five major class tradit oral agent china use treatment
diabet togeth contribut china total diabet drug
sale drug class particular biguanid form metformin
glucosidas inhibitor continu maintain steadi growth two drug class
recognis first-lin drug therapi per chines offici guidelin cfda
china food drug administr
bayer huadong
player china
mechan
slow digest
glucos meal
releas beta cell
prevent product
glucos
increas secret
weight gain
sanofi cr doubl crane
weight gain
increas risk
nordisk jiangsu hengrui
pharma bm luy hengrui
domest compani market share increas acarbos
let take look one specif gener drug market acarbos belong
-glucosidas inhibitor drug class ndrl nation drug reimburs
list rise domest player previous predomin mnc space occur
due low price advantag domest player three major player
current manufactur sell acarbos china includ bayer ag zhongmei
huadong luy pharma
bayer glucobay strong market leader product sell
acarbos past five year huadong luy pharma gain market
share challeng bayer posit market
figur volum sale acarbos show increas market share domest
figur price point per pack acarbos tablet show
substanti price advantag domest player
expect continu see huadong luy pharma increas market share
acarbos sale due price advantag gener drug space especi
kabop pass test help compani gain
market share bayer view
insulin insulin analog domest compani experienc high
mnc still china insulin market domin nordisk
sanofi current three major china player market ganle human
insulin insulin analog unit lab human insulin insulin analog tonghua
dongbao human insulin howev see strong trend domest compani gain
market share human insulin insulin analog price advantag larger
sell market team
besid domest compani lot insulin analog pipelin includ insulin
aspart insulin determir new gener rapid insulin domest
compani insulin analog approv expect domest compani gain
total around market share mnc next five year
figur china insulin market share
global mnc later entri china market product portfolio
earli entrant chines insulin market product portfolio contain
long-standing domest insulin manufactur year
oper current special produc third gener insulin
domest insulin manufactur special produc second
figur intertwin histori tonghua dongbao gan diabet sector
human insulin market tonghua dongbao kept gain market share novo
nordisk eli lilli price advantag strong grassroot sale team
tonghua dongbao current hold share china human insulin market tonghua
dongbao alreadi file new drug applic insulin glargin expect
approv believ boost compani market share
gan first china compani launch insulin glargin
countri current hold share china insulin glargin market
compani strong drug pipelin relat insulin develop expect
continu challeng mnc insulin space
estim long term domest player command around share
human insulin market current domest player domin market
insulin analog expect domest compani market share increas
tonghua dongbao unit lab gan major domest
player besid three leader compani insulin analog
figur diabet drug pipelin mention compani
new drug class mainli includ inhibitor agonist inhibitor
current domest compani approv drug within drug categori except
licens two astrazeneca meanwhil domest compani
rich pipelin new drug class current new drug class account around
china diabet drug market compar us expect
new drug class penetr increas insur coverag effect sinc
late well new domest drug launch
drug treatment therapi diabet market mani year
diabet drug market maintain steadi growth due increas number patient
fact diabet progress chronic diseas patient may need find
differ medic take diseas progress scientist investig
new drug new point insulin/glucos pathway help patient control
blood glucos level apart develop directli improv type insulin
deliv bloodstream three new drug class seen
tremend growth receiv approv use treat diabet
mechan action
inhibit degrad allow
increas insulin secret lower blood
glucos aim control blood glucos
upstream prevent risk hypoglycemia
activ allow increas insulin
secret lower blood glucos aim
control blood glucos upstream prevent
risk hypoglycemia
inhibit prevent kidney
reabsorb glucos back blood thu
three newer drug class approv cfda distribut
china exist product market domin mnc sens
opportun mani domest compani submit applic
cfda process clinic trial wait cfda approv order
expand diabet drug portfolio stay competit within new space well
figur current new drug class product market china
sinc approv inhibitor sale taken januvia one first
inhibitor approv sale china report stagger
compound-annual-growth-rate drug also quickli approv success contribut
growth diabet drug market tandem revis made ndrl
includ inhibitor expect growth rate continu
charl martineau univers toronto figur rx sale inhibitor show compound-annual-growth-rate
sale agonist also seen steadi growth china sinc product
launch exenatid enjoy compound-annual-growth-rate expect solid growth
continu sale go forward given drug lower risk hypoglycemia
greater market exposur china
figur rx sale agonist show compound-annual-growth-rate
spotlight foray china diabet sector
obtain china in-licens right two product within diabet sector
astrazeneca lilli china octob juli respect
manag indic commit growth sector
figur diabet drug portfolio show focu newer drug
licens
acquir in-licens right astrazeneca product also
integr astrazeneca diabet product sale team group commercialis
platform new busi unit addit staff indic commit
grow product manag plan expand promot effort higher
tier hospit combat novo nordisk victoza increas share market
figur therapi method current market china
ye price cut
victoza abl gain market share china due eas use fact
ad revis ndrl accept price cut
respons drive forward launch in-licens product
astrazeneca bydureon weekli administ product launch
help drive growth sector
chines compani rich pipelin new drug class hengrui sino
biopharm domest first runner segment hengrui file nda
retagliptin sino biopharm file nda saxagliptin sitagliptin
domest tradit diabet leader tonghua dongbao unit lab gan
rich pipelin drug new drug class though earli stage see
approv five drug new drug class domest compani next
gener mn sale
figur diabet drug pipelin mention compani
larg upsid compar studi
us china
china us current two largest diabet drug market china
world diabet patient share world diabet drug
market us comparison world diabet patient captur
share world diabet drug market comparison studi would like point
driver exacerb differ show upsid potenti
china grow under-penetr market except price differ china
us market penetr rate prescript gap main reason china
lag behind larg upsid potenti diabet drug market
higher diagnos rate treatment rate lead greater patient usag
share world diabet patient broken level
china us respect see still huge discrep
statist diagnos adult obtain treatment countri comment
major driver volum expect huge expans diagnosi treatment
rate signific room growth china meet us averag
still exist differ diagnos adult obtain treatment china abl
catch averag would mn adult could
contribut diabet drug market alon
figur breakdown comparison us china diabet popul show larg potenti volum growth
stark differ diabet drug product mix show upsid newer
therapi china contribut asp growth
look top diabet drug sale us china see
besid overlap insulin drug littl crossov newer drug
class us vs tradit drug class china
figur us top diabet drug sale
figur china top diabet drug sale
charl martineau univers toronto extend sale comparison look overal market share distribut
market see minuscul overlap two countri term
newer vs tradit drug class newer drug abl command combin
market share us china
figur new drug class market share
figur new drug class market share
insulin
insulin
grow trend use new drug class global point earlier
comparison us market china support find
genet differ peopl descent
creat new market diabet drug specif asian patient
studi shown asian suscept develop type diabet
lower bodi mass index european indic asian higher risk
diabet weight gain tradit measur use test
figur studi show age- bmi-standardis rate diabet
compar asian highest percentag diabet across bmi
addit studi also made specif drug use diabet
treatment test differ efficaci asian patient studi
complet look effect agonist show greater
blood glucos level reduct asian patient compar patient
studi conclus show asian patient benefit use
patient highlight differ drug efficaci
depend differ genet trait fact exist differ support
fact certain drug may work better use asian market creat slight
variat market factor look global diabet drug market
charl martineau univers toronto figur studi show differ blood glucos level reduct asian
patient inject glp medic
diabet research clinic practic
dietari differ caus rural-urban dispar greater segreg
differ asian diabet popul
today globalis economi widen gap rural-urban dispar
exist mani countri trend seen china past six
year seen china go roughli split urban
rural popul
figur although china us exhibit
trend rural-urban dispar
figur greater percentag
diabet patient urban china vs rural china
look rural urban set popul us china
see percentag diabet patient urban china
urban us due dietari differ within two countri china
rapid urbanis led mani urban dweller china live sedentari live
prone eat disord eat eat fast food factor
increas risk diabet led higher diabet popul urban china
fact higher diabet popul exist urban china suggest increas
diagnosi treatment rate diabet could expand even quickli due greater
awar public health campaign well access medic treatment
three larg domest diabet drug player china tonghua dongbao
sh unit lab ganle privat like oligopoli
grow market expect doubl next five year view besid
gain market share mnc importantli see diabet market
defens sector recent headwind includ oncolog drug price cut gpo
polici initi coverag tonghua dongbao unit lab outperform
recent quit polici headwind come china healthcar sector
regul allow mnc use clinic trial data oversea site appli
new drug applic china directli mnc quit aggress
attend nation drug price negoti includ ndrl bring larg
challeng domest compani pipelin product govern also initi
gpo gener pass test
sector averag valuat reach one-year forward pe five-year low
believ current valuat alreadi neg factor china compani
mnc cut patient assist programm smooth drug price cut
may shift sale capac innov drug save product cost
gener polici overal neg impact earn smaller
expect view
diabet name believ quit defens polici also got derat
past three month tonghua dongbao trade one-year forward price-to-earnings lower
histor averag believ stock under-valued given lead
posit china diabet sector solid organ growth launch insulin
initi coverag tonghua dongbao outperform rate
target price discount cash flow primari valuat methodolog
assum perpetu growth rate wacc expect compani
enjoy solid growth contribut strong human insulin growth move
ndrl list list enjoy reimburs higher diagnosi
rate diabet patient insulin glargin approv result surg revenu
leverag compani strong grassroot sell platform near-term
catalyst profit engin compani long term compani rich
pipelin includ best-sel diabet drug class
ultra-quick insulin major risk includ faster-than-expect pace insulin analogu
replac human insulin delay new product launch tender price cut qualiti
unit lab trade one-year forward price-to-earnings around discount
hong kong list china pharma compani see compani under-valued
stabl api profit expect ramp insulin glargin sale
initi coverag compani outperform rate tp
base ten-year multi-stag dcf model assum perpetu growth rate
wacc repres price-to-earnings like compani given lead
posit china diabet drug market ramp-up insulin glargin sale
next year approv insulin part expect stabilis
bulk intermedi price cheap valuat
note remov two-year price-to-earnings earn neg
domest leader insulin market tonghua dongbao leader
grassroot insulin market china human insulin
market share second-largest player nordisk
largest tonghua dongbao alreadi cover hospit around
counti hospit account nationwid counti
hospit insulin glargin approv within one year believ
compani domest leader china insulin market gain market
share mnc initi outperform tonghua dongbao
believ insulin glargin approv near-term catalyst
strong insulin market growth china china insulin market grew rapidli
volum compound-annual-growth-rate sale compound-annual-growth-rate per im data
domin growth diabet drug china market size
reach around bn estim market size tripl
bn growth driven age popul
grow number diabet patient higher patient diagnos rate
emerg prescrib ratio higher insulin penetr rate better
insur coverag insulin
insulin glargin approv soon tonghua dongbao rich
pipelin includ insulin analogu glargin aspart detemir
mix new oral drug compani hand nda
insulin analogu decemb expect launch
see mileston compani sale surg
immedi approv well-establish sell platform
meanwhil insulin aspart enter clinic trial phase approv
insulin aspart anoth catalyst compani view
initi tp upsid like tonghua dongbao
leadership china diabet market strong grassroot sale team
expect near-term approv blockbust drug tp base
dcf assum wacc perpetu growth rate repres
price-to-earnings major risk come delay new product approv
valuat metric
chg prev ep
number share mn
price month
price rel chart measur perform
shanghai se composit close
spot exchang rate
figur chines insulin market tripl
figur insulin account china
diabet drug sale vs us
stabilis around china
figur tonghua dongbaoto largest player
figur domest compani gain market
share insulin
tonghua donbao pharmaceut co ltd found
base tonghua china compani oper
pharmaceut industri build materi industri segment
lead player china diabet drug market
good sold
profit tax
free cash flow firm
net chang cash
blue sky valuat base insulin glargin
get approv human insulin deliv sale growth
next year
grey sky valuat base insulin glargin
get approv human insulin deliv sale
growth next year
price rel chart measur perform shanghai se
composit close
spot exchang rate
insulin market tripl
estim
compani
share human
insulin market
drug class
initi
leader grassroot insulin market
china insulin market tripl
china insulin market grew rapidli volum compound-annual-growth-rate sale compound-annual-growth-rate
per im data domin growth diabet drug china
market size reach around bn estim market size tripl
bn growth driven age popul grow popul
diabet patient higher patient diagnos rate emerg prescrib ratio
higher insulin penetr rate better insur coverag insulin though insulin
analogu growth outpac human insulin clinic advantag see human
insulin grow sale compound-annual-growth-rate short term driven reimburs rate
achiev volum share china long term tonghua dongbao
one largest beneficiari largest domest player human insulin market
insulin analogu pipelin
leader grassroot insulin market
tonghua dongbao share human insulin market china
compar second-largest player nordisk
largest tonghua dongbao leader grassroot market china cover
hospit counti level alreadi cover hospit around
counti hospit account nationwid counti
hospit implement tier medic system especi allow higher
reimburs chronic diseas lower-ti hospit grassroot market
continu outperform high-tier one strong grassroot network support
growth human insulin inclus ndrl list enabl tonghua
dongbao ramp insulin glargin well pipelin product drug
launch estim compani human insulin market share increas
win market share mnc besid compani gross margin remain
stabl see margin improv new product launch
tonghua dongbao rich pipelin includ insulin analogu glargin aspart
detemir mix new oral drug insulin
glargin compani appli nda decemb believ drug like
approv late estim compani insulin glargin gener
mn sale though quit pipelin product
earli stage develop rich pipelin new product combo therapi
support compani long-term growth well-establish diabet sell
market platform new product sale would ramp quickli launch see
compani around market share insulin glargin long run
initi outperform tp
initi outperform rate tp discount cash flow
primari valuat methodolog assum perpetu growth rate
wacc impli price-to-earnings see compani enjoy solid growth
strong human insulin growth move ndrl list list
see reimburs higher diagnos rate diabet patient
approv insulin glargin surg revenu leverag compani strong
grassroot sell platform near-term catalyst profit-engin view
compani rich pipelin includ best-sel diabet drug class
ultra-quick
replac human insulin insulin analogu delay new product launch
tender price cut qualiti manag
china insulin market tripl
china insulin market grew rapidli volum compound-annual-growth-rate sale compound-annual-growth-rate
per im data outpac sale compound-annual-growth-rate due prescript upgrad
chang human insulin insulin analog higher asp averag spend
per patient market size around bn estim tripl
bn
figur china insulin market tripl bn
note market size calcul ex-factori price compani data credit suiss estim
growth gener larger diabet patient popul increas diagnos
rate higher penetr insulin treatment better patient complianc larger volum
insulin use per patient treatment upgrad within insulin treatment human insulin
insulin analog
figur catalyst drive insulin market growth china
rate insulin
upgrad
human insulin
insulin account around china anti-diabet drug sale versu
global market leav insulin signific potenti grow term
market share anti-diabet market besid penetr rate insulin among
diabet patient around
insulin market challeng sglt past two year
global howev china shown differ trend enjoy strong insulin growth due
better price efficaci ratio better insur coverag insulin especi human
monotherapi combin therapi new drug class slgt
could delay usag insulin quit head-to-head studi compar insulin
glargin receptor agonist signific differ regard
reduc level significantli associ decreas weight
figur outpac insulin
past two year global
figur new drug class account
global diabet drug sale
gener insulin
gener insulin
gener insulin
gener insulin
compani data ad provid product annual report
compani data ad provid product
sale third-gener insulin challeng contract
sale growth particularli latter much outpac insulin global
could also seen best-sel diabet drug us
new drug class account five top-sel ten diabet drug us
figur insulin market share start contract global
gener insulin
gener insulin
howev china see differ trendth growth insulin still quit strong
due insulin better price efficaci ratio higher insur reimburs rate larger
ratio undiagnos patient insulin account china
diabet drug market market share
basic hypoglycem drug -glycosidas inhibitor sulfonylurea biguanid
famili still account around market data show
chines diabet patient quit under-diagnos indic larg market potenti
insulin ahead
pocket much higher insulin analog
patient especi grassroot patient quit price-sensit lifelong-usag drug
diabet drug fall categori insulin fulli cover ndrl
sinc februari drive new-pati usag
global insulin market share diabet drug start decreas challeng
new drug class dont see trend play china short-to-media
term insulin enjoy market share growth replac basic hypoglycem next
five eight drug better insur coverag new drug class start
gain market share insulin driven price especi out-of-pocket price
insulin new drug class shown
figur price comparison major diabet drug china
pocket
note assum pocket payment ndrl inclus compani data credit suiss estim
 limit
none limit
figur out-of-pocket cost major diabet drug
figur insulin account global anti-
diabet drug market
figur insulin account china
anti-diabet drug market
gener
gener
human insulin market share china remain
insulin analogu replac human insulin global includ china trend
continu end human insulin still abl retain around market
share vs view see strong human insulin growth china driven
patient upgrad prescript classic oral hypoglycem agent insulin
reimburs human insulin next three year
three gener insulin till gener shown clinic
superior predecessor thu strong trend china global third-
gener insulin insulin analogu replac second-gener human insulin
figur gener insulin show clinic superior previou
type diabet
compar first gener
similar insulin secret
human bodi lower
allergi rate insulin resist
rate smaller dosag
compar second
risk immedi start work
inject better control
one day dosag
figur human insulin market share stabilis
rapidli lose market share us
stabilis around china
insulin analogu rapidli replac human insulin china sinc took
half market howev human insulin market share rebound
sinc move list list ndrl mean human
insulin fulli reimburs public medic insur meanwhil ndrl
restrict insulin analogu reimburs patient whose glucos level
reach ideal level use insulin oral agenc
see around yoy growth human insulin market next two year
driven ndrl coverag way motiv patient current use classic
oral hypoglycem agent switch use insulin earlier increas volum
use patient channel check show lot patient use classic
hypoglycem agent despit effici control glucos level use
inadequ dosag save cost
long run insulin analogu outpac human insulin growth due clinic
advantag view estim human insulin market share stabilis around
long run year sharp decreas human insulin market share
stabilis around sinc consid lower level per capita
absenc commerci medic insur human insulin compani strong sale
network grassroot market estim china human insulin market share stabilis
around long run
figur tonghua dongbao human insulin revenu growth driven higher insulin penetr rate
treatment case diagnos case
insulin insulin
tonghua dongbao patient china
leader grassroot insulin market
tonghua dongbao gansulin recombin insulin api gener
bn sale achiev yoy growth share
china human insulin market second-largest player nordisk
largest tonghua dongbao leader grassroot market china cover
hospit counti level alreadi cover hospit around
counti hospit account nationwid counti hospit
implement tier medic system especi allow higher
reimburs chronic diseas lower-ti hospit grassroot market
continu outperform high-tier one
tonghua dongbao launch gansulin first domest recombin human insulin
five product gansulin brand differ mixtur cover short-
term isophan insulin human insulin seen sale compound-annual-growth-rate
see compound-annual-growth-rate driven insur reimburs
figur insulin product tonghua dongbao differ mixtur
start work
tonghua dongbao diabet drug sales-repres cover
hospit around counti hospit account nationwid
counti hospit insulin growth driven low-tier market data
pdb sampl hospit mainli includ class class ii hospit tier tier
citi show human insulin hospit contract
see strong trend shift human insulin insulin analog hospit
especi new patient
howev human insulin grow rapidli grassroot market hospit county-
level citi channel check show new patient
grassroot market start insulin treatment use human insulin ratio
around larg hospit higher-ti citi besid quit polici
announc regard implement hierarch medic system
allow higher reimburs consult fee low-tier hospit
hierarch medic system patient especi chronic diseas
retain local hospit pharma sale citi hospit grew yoy
versu counti hospit
govern encourag treatment chronic diseas patient commun clinic
counti level hospit set lower consult fee hospit
provid higher reimburs rate system compani tonghua
dongbao well-establish grassroot sell network benefit
win market share mnc
human insulin market still domin mncsnova nordisk market share
around tonghua dongbao rank third
mnc shift resourc penetr insulin analogu sale nordisk
insulin analogu sale flat sinc tonghua dongbao strong sell
network grassroot market enabl keep win market share mnc
meanwhil estim tonghua dongbao market share human insulin increas
insulin market
figur tonghua dongbao market share
human insulin keep increas
besid tonghua dongbao human insulin sell eli lillys/nova
nordisk price given hospit signific pressur control
insur reimburs budget doctor incent prescrib domest product
tonghua dongbao market share human insulin market much larger
second domest player unit lab market share
tonghua dongbao larger sell platform unit lab grassroot market
grant tonghua dongbao higher market share insulin glargin long
term approv
tonghua dongbao gross margin surg
sinc compani largest human insulin ferment system
china two scale reaction tank compar competitor
allow achiev higher gross margin compani maintain human
insulin tender price see trend continu given price advantag
insulin analogu new oral-class drug
sell cost per sale admin expens per sale also steadili come
sinc scale impact compani net margin
estim sell market cost percentag sale go slightli
reach commercialis new product meanwhil
compani net margin continu rise steadili driven higher gross margin
lower admin expens per sale scale impact cost
figur steadi rise gross margin/net profit
figur net margin improv slightli next
apart launch human insulin tonghua dongbao rich pipelin includ
insulin analogu glargin aspart detemir mix new oral drug
compani submit nda insulin analogu decemb
expect launch meanwhil insulin aspart enter clinic
trial phase rich pipelin support compani long-term growth new
product combo therapi well-establish diabet drug sell
market platform new product sale ramp quickli launch
insulin glargin launch
among insulin analogu insulin glargine/insulin aspart inject process
fastest ndr glargin submit decemb expect
launch view insulin glargin long-act insulin analog
origin develop sanofi brand lantu need subcutan
inject per day mode action insulin glargin allow peakless profil
help reduc nocturn hypoglycemia lantu rank best-
sell diabet drug sinc achiev peak sale bn sale
start go challeng biosimilar new drug class sanofi new insulin
china insulin glargin sale increas compound-annual-growth-rate reach
mn forecast market grow compound-annual-growth-rate reach mn
figur lantu reach peak sale bn
us bn
three player china insulin glargin marketsanofi ganle
unit lab sanofi still domin market share unit labss insulin
glargin approv may reach mn sale first half year
launch believ tonghua dongbao one major player insulin
glargin market market share long term support diabet drug
direct sale team compani also done studi compar head-to-head insulin
glargin sanofi origin drug lantu clinic trial result show
efficaci safeti
figur tonghua dongbao glargin insulin sale ramp strong direct sale network
treatment case diagnos case
glargin insulin insulin
tonghua dongbao patient china
factor success rate rmb
cooper adocia ultra-rapid insulin
tonghua dongbao cooper adocia develop ultra-rapid insulin
biochaperon bc lispro china asian except japan region
deal tonghua dongbao gain exclus right develop bc lispro bc
combo region deal strengthen compani diabet drug
pipelin support long-term growth
bc lispro ultra-rapid insulin act rapidli approv insulin
analogu enter clinic trial phase europ bc combo
neutral pre-mix insulin combin insulin glargin ultra-rapid insulin show
advantag includ act rapidli stabli clinic trial phase europ
enter clinic trial phase ii europ
tonghua dongbao made mn up-front payment bc lispro mn
up-front fee bc combo rel mileston fee paid clinic trial
reach certain stage within region authoris tonghua dongbao
figur mileston payment tonghua dongbao adocia
enter phase
approv first author region
enter phase
approv first authoris region
tonghua dongbao invest huaguang technolog build diabet patient
monitor system includ glucos monitor devic e-platform
compani built system base doctor app patient data
upload app glucos monitor devic doctor provid advic
patient base data system provid patient accur
time advic could improv patient complianc rate tonghua dongbao
initi outperform tp
tonghua dongbao deliv sale compound-annual-growth-rate net profit compound-annual-growth-rate
strong human insulin growth support higher insulin penetr rate china
grow market share see compani sales/net profit grow
contribut human insulin ndrl list inclus glargin insulin new
launch stabl oper busi segment compani revenu growth
outpac previou year due properti revenu mn
sustain
figur revenu rmb mn grow
compound-annual-growth-rate
figur net profit rmb mn grow
compound-annual-growth-rate
insulin api inject
insulin api inject
use free cash flow valuat primari valuat mechan initi coverag
tonghua dongbao outperform rate tp base ten-year
multi-stag dcf model assum perpetu growth rate wacc
capital-expenditure rate chang revenu
chang work capit
npv cash-flow
npv perpetu
number share
debt
pre-tax debt
after-tax debt
equiti
risk-fre rate return
equiti
weight averag capit
tonghua trade price-to-earnings around premium larg pharma
compani believ premium well justifi strong diabet market growth
lead posit diabet drug market defens stanc toward price-
cut polic valuat stay rel stabl compar larg pharma
compani defens recent sector headwind includ challeng
mnc price-cut pressur
third-gener insulin replac second-gener faster expect tonghua
dongbao major profit come human insulin whole human insulin market
pressur third-gener insulin replac second-gener faster
expect besid competit second-gener insulin market anoth risk
compani
delay new product approv drug approv uncertainti one major risk
two insulin analogu insulin glargin insulin aspart delay approv pipelin
signific neg impact compani
drug price-cut public medic insur fund run margin balanc
regul lot pressur control medic expens tender drug price-
cut one major risk tonghua dongbao facingit lead lower margin
holt view tonghua dongbao
holt methodolog use proprietari perform measur known
return invest cfroi approxim econom return
estim averag real intern rate return earn firm portfolio
project constitut oper asset firm cfroi directli compar
real cost capit investor real discount rate see firm creat
econom wealth remov account inflat distort cfroi allow
global compar across sector region time comprehens metric
tradit roe
appli key cs analyst estim holt framework result
valuat scenario valuat initi use ten year key analyst estim drive
cfroi forecast proprietari algorithm determin rate fade toward
figur credit suiss analyst estim holt
tonghua donbao pharmaceut co ltd found base tonghua
china compani oper pharmaceut industri build materi
industri segment lead chines anti-diabet drug manufactur provid
biolog product tradit chines medicin chemic supplement appli
treatment diabet cardiovascular cerebrovascular diseas human
insulin approv first domest human insulin approv china
compani human insulin also approv ema export
countri region
compani rich pipelin includ almost diabet drug class monocular
antibodi treat rheumatoid-arthr patient finish clinic trial phase
insulin glargin appli nda decemb meanwhil insulin aspart
clinic trial phase
tonghua dongbao key manag member stay compani
ten year founder mr li yikui still chairman graduat
biolog peke univers
juli compani stock price drop mr li cong ceo head
sale step head sale compani announc would step
charl martineau univers toronto posit would stay compani therebi preclud
possibl move competitor believ compani quit matur
sale structur mr li departur depart limit impact
compani oper neg alreadi factor
date appoint
mr li work chairman compani dongbao industri group li
establish dongbao industri group compani mr li graduat peke
univers bachelor degre biolog senior engin
liscens certifi pharmacist
work ceo compani sinc jan jan dec li
work market director gansulin ceo assist dec dec
work market director shanghai offic novo nordisk china
juli dec taught patholog tongji univers mr li graduat
tongji univers bachelor degre medic
mr wang work chief account board secretari compani
graduat jilin univers financ econom bachelor degre
account
mr leng respons gener manag technolog support insulin
project genet engin drug graduat liaon normal
univers doctor degre cytobiolog leng receiv bachelor
degre chemistri jilin institut chemic technolog
mr chen respons oral diabet drug tcm nutrit product chen
use work manag depart compani current pursu
doctor degre financ wuhan univers sinc chen receiv bachelor
degre pharmaceut analysi shenyang pharmaceut univers
domest player ramp
initi outperform initi coverag unit lab new
leader china insulin market unit lab second domest
compani approv human insulin insulin analogu china
ganle compani share china human insulin market
began commercialis insulin glargin like
compani lead posit china diabet market see
pressur intermedi profit
china diabet market grow compound-annual-growth-rate china largest
number diabet patient world-wide account one-third world
diabet market market under-penetr due less focu chronic
diseas manag see market grow compound-annual-growth-rate next
five year driven increas penetr rate better insur coverag
upgrad treatment unit lab one major winner
due diabet drug segment high technic entri barrier
surg insulin glargin sale approv insulin aspart see
compani insulin glargin deliv mn sale
first/second full year commercialis unit lab
submit approval-appl insulin aspart expect approv
come see import catalyst
compani major risk price pressur intermedi price
initi outperform tp tp base
ten-year multi-stag dcf model assum perpetu growth rate
wacc repres price-to-earnings like compani leadership
china diabet drug market ramp-up insulin glargin sale next
year expect approv insulin aspart stabil
bulk intermedi price cheap valuat major risk focu
delay new product approv price may go
valuat metric
chg prev ep
number share mn
price month
price rel chart measur perform
hang seng close
spot exchang rate
figur origin insulin glargin lantu
peak sale bn global
figur unit lab insulin
glargin market share long run
figur ramp sale insulin glargin
compani sinc approv
figur price gradual recov
figur margin keep improv
unit lab produc distribut pharmaceut product
capsul human insulin insulin analog
blue sky price base sale compound-annual-growth-rate api
next three year insulin glargin reach sale
grey sky price base declin api
revenu everi year next three year insulin glargin
reach sale
good sold
profit tax
free cash flow firm
net chang cash
price rel chart measur perform hang seng
close
spot exchang rate
charl martineau univers toronto leader
human insulin
rich pipelin cover
significantli
initi
outperform
lead new player china insulin market
unit lab second domest compani approv human insulin
insulin analogu china ganle compani share china
human insulin market began commercialis insulin glargin
estim human insulin busi see volum compound-annual-growth-rate sale compound-annual-growth-rate
next three year driven ndrl list inclus win market share
mnc insulin glargin approv earli reach mn sale
estim insulin glargin deliv mn sale
increas treatment rate diabet higher penetr rate insulin analog
grow market share unit lab major driver insulin glargin busi
rich pipelin diabet drug
compani rich pipelin includ major diabet drug class insulin
aspart anoth blockbust insulin approv short run submit
insulin aspart product applic guangdong fda novemb
finish phase clinic trial march expect compani insulin aspart
approv start sale contribut insulin aspart one
mn peak sale global model forecast insulin aspart contribut
mn sale long run around
benefit grow intermedi price
intermedi bulk medicin busi turn around compani
intermedi product busi repres amoxicillin incur loss
segment result turn around loss mn
profit mn bulk medicin segment record revenu approxim
bn gener mn profit intermedi product
price increas given restrict suppli due stricter environ
protect regul see intermedi sale growth acceler
remain stabl weight averag ex-factori price increas
long-term contract expiri see intermedi segment profit contribut peak
spot price alreadi peak june suppli becom loos
manufactur start product recent regul loosen environ
standard region manufactur player may challeng
initi outperform tp
initi unit lab outperform tp base ten-
year multi-stag dcf model assum perpetu growth rate wacc
repres price-to-earnings like compani lead posit china
diabet drug market expect sale ramp-up insulin glargin next year
expect approv insulin aspart besid intermedi busi
turn around gener mn net profit unalloc
cost busi grow maintain stabl weight
averag ex-factori price growth delay due long-term contract howev
spot price peak june product competitor major risk
china
unit lab second domest compani approv human insulin
insulin analogu china ganle compani share china
human insulin market began commercialis insulin glargin
insulin glargin approv earli reach mn sale
estim insulin glargin deliv mn sale hand insulin aspart
product applic guangdong fda novemb approv insulin
aspart enrich diabet drug portfolio establish lead posit
china diabet market see strong insulin glargin sale approv
insulin aspart near-term catalyst compani
estim diabet product contribut compani sale
long run estim compani share
china insulin market full insulin portfolio includ human insulin insulin glargin
insulin aspart insulin detemir
figur diabet drug mileston unit lab
approv
approv
applic dispos
ind approv
solid growth human insulin
compani commercialis human insulin fourth-largest human
insulin seller china market share sale increas
estim see volum compound-annual-growth-rate sale compound-annual-growth-rate
next three year driven ndrl list inclus market share gain
mnc expect price stabl next three year consist
analys insulin still domin diabet drug sale china versu new
drug class lead growth insulin sale contract
past two year us besid see long term human insulin still
maintain volum market share china line uss case studi human
insulin retain stabl market share sharpli replac insulin
figur unit lab human insulin sale see
compound-annual-growth-rate
figur unit lab human insulin volum
see compound-annual-growth-rate
ramp insulin glargin sale
unit lab insulin glargin approv januari commercialis may
gener name uslen compani sold insulin glargin
pen gener mn first half-year launch insulin glargin
avail dispos refil pen-typ lantu avail pre-filled
dispos pen basalin refil pen-typ estim uslen sale reach
mn achiev market share long
insulin glargin long-act insulin analog origin develop sanofi
brand lantu need subcutan inject per day mode action
insulin glargin allow peakless profil help reduc nocturn
hypoglycemia lantu rank best-sel diabet drug sinc
reach peak sale bn sale start go challeng
biosimilar new drug class sanofi new insulin glargin toujeo
china insulin glargin sale increas compound-annual-growth-rate reach mn
estim market continu grow compound-annual-growth-rate reach
mn growth driven higher penetr rate insulin
prescript switch human insulin insulin analogu
figur lantu reach peak sale bn
us bn
figur china glargin sale went sharpli
three player china insulin glargin market sanofi ganle
unit lab sanofi still domin market share first year
launch uslen tender bid fujian chongq heilongjiang henan
charl martineau univers toronto hebei guangdong shanxi tibet estim uslen sale reach
mn market share long term
figur uslen sale
figur compani market share glargin
tender price uslen unit lab basalin ganle around
discount tender price lantu sanofi origin drug new ndrl
reimburs insulin analogu restrict type diabet patient
type patient whose blood glucos could effect control oral drug
insulin patient could reimburs public insur monthli cost
lantus/basalin/uslen price gap larg enough
patient choos domest product meanwhil hospit lot
pressur control medic insur cost besid multi polici publish
regul motiv doctor prescrib generics/ biosimilar replac origin
figur price comparison insulin glargin sanofi ganle
pocket cost
rmb/month
pocket cost
rmb/month
rich pipelin diabet drug
insulin aspart approv near term
unit lab submit insulin aspart product applic guangdong fda
novemb finish phase clinic trial march estim
compani insulin aspart approv start contribut sale
model forecast insulin aspart contribut mn sale
insulin aspart fast-act insulin analogu first develop novo nordisk
brand novolog drug effect could peak within minut inject
alway use minut meal could also combin
intermediate- long-act insulin novolog mix premix aspart
protamin suspens insulin aspart inject compar insulin
analogu insulin aspart use diabet patient liver kidney problem
appear higher risk low blood sugar episod
figur novolog reach mn peak sale
nordisk insulin aspart approv china sale reach
mn china still insulin aspart supplier china
three domest compani late stage develop insulin aspart ganle
unit lab appli nda januari tonghua dongbao finish clinic
trial march
charl martineau univers toronto figur statu insulin aspart china
domest compani get insulin aspart approv start gain
market share novo nordisk develop grassroot market novo nordisk insulin
aspart sale mainli larg class hospit tier tier citi believ
domest compani leverag well-establish platform increas total
market share total first year launchshar three major player
ganle unit lab tonghua dongbao see three domest compani
achiev market share long run unit lab around
figur domest player market share ramp insulin aspart
benefit grow intermedi price
unit lab intermedi product busi repres amoxicillin
incur loss divis turn around loss mn
profit mn unalloc expens bulk medicin
segment record revenu approxim bn gener mn
profit intermedi product price increas given
restrict suppli due stricter environ protect regul estim two
segment contribut stabl profit stabl price next two year
hand competitor may start product high price could drag
price profit unit lab
figur segment-wis profit unalloc
price keep go
acid central compon penicillin -lactam antibiot
gener penicillium unit lab largest produc global
capac price hit bottom septemb around
per wind data price gradual increas may remain
stabl sinc intermedi product repres incur loss
due under-pressur price intermedi product segment gener mn
net profit due recov price howev exist capac run
almost would make volum increas unachiev short term without
figur unit lab ex-factor price slightli
delay spot trade price
howev compani ex-factori price recov delay compar
spot trade price due fix price contract averag spot price increas
yoy ex-factori price compani went
see averag ex-factor price increas maintain price
price remain stabl second half year
price driven due limit suppli stricter environ protect
rule unit lab suspend product due environ protect
regul start construct new capac inner mongolia
intermedi product bulk product move new manufactur site
compli stricter environ standard
smog quit critic issu china past year winter especi
northern china last year pharma manufactur suspend hebei
shijiazhuang quit big pharma compani locat suspend
product competitor capac lead under-suppli market increas price
side high spot price competitor may will spend
reconstruct manufactur facil compli environ standard
resum product recent regul loosen environ standard motiv
develop economi resum manufactur competitor especi weiqida
pharma great challeng price
figur capac suppli
sensit test price
base histor volum sale profit data done sensit test
intermedi product base data assum
manufactur cost fix capac mostli fulli utilis use
averag price baselin gener mn net profit unalloc cost
estim averag price intermedi product increas yoy
segment contribut mn net profit
charl martineau univers toronto figur sensit test intermedi product price
price api may face challeng china regul think loosen
extend product chain bulk product
unit lab alreadi reach full utilis capac howev better
profit could made higher profit margin expand product chain
manag guid use produc amoxicilin bulk anoth
import bottleneck amoxicilin manufactur limit suppli diphenhydramin
compani alreadi start manufactur diphenhydramin second quarter
diphenhydramin suppli compani extend product
chain produc amoxicilin bulk estim segment profit bulk medicin
could reach mn
compani amoxicillin capsul pass bioequival test april
leader china amoxicilin market around market share sampl hospit
upsid market share avail compani pass test
view see usag antibiot sale remain stabl sharpli
decreas past three year regul anti-abus antibiot movement
china
initi outperform tp
unit lab revenu mainli come finish product intermedi product
bulk medicin three segment contribut total sale
incur larg loss due under-pressur intermedi bulk medicin sale
estim compani net profit surg gener net profit
estim net profit mn
driven stabl bulk medicin intermedi product
price solid human insulin growth move ndrl list ramp-up
figur unit lab sale growth recov
rmb mn
figur net profit surg rmb mn
figur growth segment insulin domin growth
estim unit lab finish product deliv sale growth
driven solid human insulin sale ndrl list inclus ramp-
insulin glargin sale second year launch insulin aspart launch
estim gener mn sale year view besid
compani amoxicillin pass test allow increas
market share current view
believ intermedi product sale recov driven higher price
price hit bottom septemb around per wind data price
gradual increas may remain stabl sinc ex-
factori price recov delay compar spot trade price due fixed-
price contract averag spot price increas yoy
ex-factori price compani went see averag ex-factori price
increas maintain price price remain stabl
second half year estim intermedi product sale increas
bulk medicin gener sale record segment revenu
bn segment profit around mn bulk medicin mainli includ semi-
synthet penicilin cephalospor b-lactamas inhibitor whose price gradual
increas due less suppli stricter environ protect rule estim
bulk medicin segment deliv sale growth
driven gradual increas price utilis
figur margin compani
gener administr
sale market
gross margin estim compani gross margin gradual increas
grow intermedi product bulk medicin price higher ratio finish
sale market cost percentag sale see sale market cost
percentag sale stabl sale increas
 percentag sale estim increas gradual driven clinic
trial enter late stage compani focu drug
unit lab stock trade price-to-earnings around discount hong
kong-list peer compani lead posit diabet drug sector
turnaround profit believ compani discount
capital-expenditure rate chang revenu
chang work capit
npv cash-flow
npv perpetu
number share
debt
pre-tax debt
after-tax debt
equiti
risk-fre rate return
equiti
weight averag capit
use free cash flow valuat primari valuat mechan initi unit
lab outperform rate tp base multi-stag dcf
model assum perpetu growth rate wacc
compani trade price-to-earnings around discount hong kong list peer
believ lead posit china diabet market block buster drug
expect short run compani under-valued
drug price may face polici risk chines govern aggress target
cut drug price due pressur public medic insur payment pool sharp
price cut impact compani margin profit
drug price may go price sharpli increas sinc june
reach peak june may face price pressur long term
manufactur resum product high price
delay approv new product compani submit insulin aspart registr
approv delay approv new product neg impact compani
loosen environment standard slow econom growth chins
govern consid loosen environ control price may go
manufactur resum product
use sotp method back check tp alloc unalloc cost
segment base sale contribut estim ep segment reach
valuat per share similar tp appli price-to-earnings
intermedi price-to-earnings bulk medicin price-to-earnings finish product
reason use multipl unit lab finish product much smaller
tonghua dongbao multipl insulin gener finish
product semi-synthet penicillin antibiot cephalosporin antibiot
multipl insulin higher price risk
overal give larg discount unit lab compar tonghua dongbao
unit lab pure player diabet sector intermedi bulk medicin
finish product trade larg discount diabet drug
holt view unit lab
holt methodolog use proprietari perform measur known
return invest cfroi approxim econom return
estim averag real intern rate return earn firm portfolio
project constitut oper asset firm cfroi directli compar
real cost capit investor real discount rate see firm creat
econom wealth remov account inflat distort cfroi allow
global compar across sector region time comprehens metric
tradit roe
appli key cs analyst estim holt framework result
valuat scenario consist outperform rate scenario use ten
year key analyst estim avail drive cfroi forecast
proprietari algorithm determin rate fade toward long-run averag cfroi
figur credit suiss analyst estim holt
mr tsoi hoi chairman mr tsoi join group supervisor
qualiti control depart respons supervis product process
hong kong yuen long plant ensur complianc
manufactur practic mr tsoi graduat tongji medic univers bachelor
degre medicin bachelor degre surgeri mr tsoi brother
ms choy siu chit execut director compani
mr leung ed vice-chairman cfo compani secretari
compani mr leung fellow member hong kong institut certifi public
account member associ intern account fellow
member taxat institut hong kong hold bachelor account
degre univers bolton postgradu certif busi administr
univers leicest unit kingdom respect mr leung previous
work intern account firm also held posit account
manag subsidiari chinney invest ltd compani whose share list
main board stock exchang mr leung year experi
account financ manag busi administr mr leung join
group respons overse financi matter group
ms choy siu chit ed ms choy join group handl drug
master file submiss relat group amoxicillin bulk medicin fda
pursuant group becam holder drug master file type ii dmf
relat amoxicillin bulk medicin ms choy also hold directorship
certain subsidiari compani pass privat equiti invest fund
advanc class organ beij univers distinct ms choy
director mighti brokerag asia limit princip provid brokerag
secur trade servic hong kong sister mr tsoi hoi
execut director chairman compani
mr yu ed vice-president mr graduat medic school southeast
univers prc formerli known nanj railway medic school
bachelor degre medicin graduat serv teach staff
member school year mr join group promot
vice presid group gener manag china sale divis
ms zou xian hong ed vice-president ms zou graduat nanj medic colleg china
pharmaceut univers obtain execut master busi
administr hunan univers june ms zou obtain doctor
manag scienc engin busi school central south
univers ms zou year experi prc pharmaceut industri
ms zou employ teacher hunan medic middl school
prior join group sinc join group respons
sale manag group
ms zhu su yan ed vice-president ms zhu graduat medic school southeast
univers prc formerli known nanj railway medic school
bachelor medicin surgeri degre grant degre execut
master busi administr busi school nanj univers
ms zhu work nanj gulou hospit neurosurgeon
join join group earli serv region
manag jiangsu provinc manag vice presid nation hospit
develop depart deputi gener manag prc sale team etc
ms zhu extens experi sale market pharmaceut product
prc princip respons sale market group
product prc
compani mention price
